Yuko Fujiwara

Yuko Fujiwara

Auto-generated profile, based on publicly available information

Yuko Fujiwara

Graduate School of Agriculture, Kyoto University

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WLWenchu Lin
Wenchu Lin
JCJian Cao
Jian Cao
JLJiayun Liu
Jiayun Liu
MBMichael L. Beshiri
Michael L. Beshiri
YFYuko Fujiwara
Yuko Fujiwara
Qin YanQin Yan
Qin Yan
Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation ofRbp2decreases tumor formation and prolongs survival inRb1+/−mice andMen1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy.

10 November 2016 in Blood
Verified
Journal Article
Open access
PDF file
ESElenoe C. Smith
Elenoe C. Smith
SLSidinh Luc
Sidinh Luc
DCDonyell M. Croney
Donyell M. Croney
MWMollie B. Woodworth
Mollie B. Woodworth
LGLuciano C. Greig
Luciano C. Greig
SOStuart H. Orkin
Stuart H. Orkin
Key Points: Deletion of the erythroid enhancer of Bcl11a from the mouse genome does not affect viability or Bcl11a expression in nonerythroid lineages. Elevated levels of γ-globin in Bcl11a enhancer–deleted mice are comparable to those in erythroid-specific Bcl11a gene knockout mice.

1 September 2003 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
JFJudith C Fleming
Judith C Fleming
ETElena Tartaglini
Elena Tartaglini
RKRyosuke Kawatsuji
Ryosuke Kawatsuji
DYDavid Yao
David Yao
YFYuko Fujiwara
Yuko Fujiwara
ENEllis J Neufeld
Ellis J Neufeld

14 September 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
BLBin E. Li
Bin E. Li
GLGrace Y. Li
Grace Y. Li
WCWenqing Cai
Wenqing Cai
QZQian Zhu
Qian Zhu
DSDavide Seruggia
Davide Seruggia
SOStuart H. Orkin
Stuart H. Orkin
CRISPR/Cas9 screening approaches are powerful tool for identifying in vivo cancer dependencies. Hematopoietic malignancies are genetically complex disorders in which the sequential acquisition of somatic mutations generates clonal diversity. Over time, additional cooperating mutations may drive disease progression. Using an in vivo pooled gene editing screen of epigenetic factors in primary murine hematopoietic stem and progenitor cells (HSPCs), we sought to uncover unrecognized genes that contribute to leukemia progression. We, first, modeled myeloid leukemia in mice by functionally abrogating both Tet2 and Tet3 in HSPCs, followed by transplantation. We, then, performed pooled CRISPR/Cas9 editing of genes encoding epigenetic factors and identified Pbrm1/Baf180, a subunit of the polybromo BRG1/BRM-associated factor SWItch/Sucrose Non-Fermenting chromatin–remodeling complex, as a negative driver of disease progression. We found that Pbrm1 loss promoted leukemogenesis with a significantly shortened latency. Pbrm1-deficient leukemia cells were less immunogenic and were characterized by attenuated interferon signaling and reduced major histocompatibility complex class II (MHC II) expression. We explored the potential relevance to human leukemia by assessing the involvement of PBRM1 in the control of interferon pathway components and found that PBRM1 binds to the promoters of a subset of these genes, most notably IRF1, which in turn regulates MHC II expression. Our findings revealed a novel role for Pbrm1 in leukemia progression. More generally, CRISPR/Cas9 screening coupled with phenotypic readouts in vivo has helped identify a pathway by which transcriptional control of interferon signaling influences leukemia cell interactions with the immune system.

26 September 2024 in Blood
Verified
Journal Article
Closed access
SDSarah Ducamp
Sarah Ducamp
ASAnoop K. Sendamarai
Anoop K. Sendamarai
DCDean R. Campagna
Dean R. Campagna
DCDesmond Wai Loon Chin
Desmond Wai Loon Chin
YFYuko Fujiwara
Yuko Fujiwara
MFMark D. Fleming
Mark D. Fleming
X-linked sideroblastic anemia (XLSA) and X-linked protoporphyria (XLPP) are uncommon diseases caused by loss-of-function and gain-of-function mutations, respectively, in the erythroid form of 5-aminolevulinic acid synthetase (ALAS), ALAS2, which encodes the first enzyme in heme biosynthesis. A related congenital sideroblastic anemia (CSA) is due to mutations in SLC25A38 (solute carrier family 25 member A38), which supplies mitochondrial glycine for ALAS2 (SLC25A38–CSA). The lack of viable animal models has limited the studies on pathophysiology and development of therapies for these conditions. Here, using CRISPR-CAS9 gene editing technology, we have generated knockin mouse models that recapitulate the main features of XLSA and XLPP; and using conventional conditional gene targeting in embryonic stem cells, we also developed a faithful model of the SLC25A38-CSA. In addition to examining the phenotypes and natural history of each disease, we determine the effect of restriction or supplementation of dietary pyridoxine (vitamin B6), the essential cofactor of ALAS2, on the anemia and porphyria. In addition to the well-documented response of XLSA mutations to pyridoxine supplementation, we also demonstrate the relative insensitivity of the XLPP/EPP protoporphyrias, severe sensitivity of the XLSA models, and an extreme hypersensitivity of the SLC25A38-CSA model to pyridoxine deficiency, a phenotype that is not shared with another mouse hereditary anemia model, Hbbth3/+ β-thalassemia intermedia. Thus, in addition to generating animal models useful for examining the pathophysiology and treatment of these diseases, we have uncovered an unsuspected conditional synthetic lethality between the heme synthesis–related CSAs and pyridoxine deficiency. These findings have the potential to inform novel therapeutic paradigms for the treatment of these diseases.

17 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSarah Bowling
Sarah Bowling
DSDuluxan Sritharan
Duluxan Sritharan
FOFernando G. Osorio
Fernando G. Osorio
MNMaximilian Nguyen
Maximilian Nguyen
PCPriscilla Cheung
Priscilla Cheung
FCFernando D. Camargo
Fernando D. Camargo
Tracing the lineage history of cells is key to answering diverse and fundamental questions in biology. Particularly in the context of stem cell biology, analysis of single cell lineages in their native state has elucidated novel fates and highlighted heterogeneity of function. Coupling of such ancestry information with other molecular readouts represents an important goal in the field. Here, we describe the CARLIN (for C RISPR A rray R epair LIN eage tracing) mouse line and corresponding analysis tools that can be used to simultaneously interrogate the lineage and transcriptomic information of single cells in vivo. This model exploits CRISPR technology to generate up to 44,000 transcribed barcodes in an inducible fashion at any point during development or adulthood, is compatible with sequential barcoding, and is fully genetically defined. We have used CARLIN to identify intrinsic biases in the activity of fetal liver hematopoietic stem cell (HSC) clones and to uncover a previously unappreciated clonal bottleneck in the response of HSCs to injury. CARLIN also allows the unbiased identification of transcriptional signatures based on in vivo stem cell function without a need for markers or cell sorting.